TS Nexgen티에스넥스젠

TS Nexgen shows deep losses and a share price flat across all periods, with a rehabilitation application dismissed in September.

TS Nexgen, a Korean maker of power plant dampers, marine SOx dampers and Busway power distribution systems, reported trailing twelve-month revenue of ₩12.2B against an operating loss of ₩3.0B and a net loss of ₩23.8B as of H1 2026. The share price closed at ₩1,710 on 2026-10-28, with no change over one month, three months or one year, and the 52-week high and low are both ₩1,710. The data does not include analyst ratings, forecasts or a fair value estimate.

What stands out

• Revenue has fallen for two years, from ₩26.5B in 2023 to ₩14.5B in 2025, with the operating margin at -40.4% in 2025.
• Net loss reached ₩38.6B in 2025, and liabilities are 72.1% of equity with cash of ₩0.8B against borrowings of ₩1.1B.
• Free cash flow over the trailing period was -₩2.1B, and the company pays no dividend.
• The August 2026 half-year review filing includes an adverse opinion and notes capital impairment of 50% or more, with equity under ₩1B.
• In September 2026 a court dismissed an application for rehabilitation proceedings, and a filing dated 2026-10-28 amends a major sales or supply contract; the filings do not give the contract's details.
• Foreign ownership is 0%, and the 20-day investor flows are small, with retail net buying of ₩184.9M and foreign net selling of ₩40.9M.

What to watch

• Whether the amended half-year report and the amended supply contract filing change the reported figures or terms.
• Any further filings on capital impairment, equity levels or the going-concern position named in the August review.
• The company's neurostimulation subsidiary NeuroSona is mentioned in the profile, but the data gives no details on its progress or revenue.